1010120-55-4

Basic information

• Product Name: 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine
• Synonyms: 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine;5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine;2-AMino-5-broMo-[1,2,4]triazolo[1,5-a]pyridin;2-Amino-5-bromo-1,2,4-triazolo[1,5-a]pyridine
• CAS NO: 1010120-55-4
• Molecular Formula: C₆H₅BrN₄
• Molecular Weight: 213.0347
• EINECS: 1592732-453-0
• Mol File: 1010120-55-4.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• Density: 2.09
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.99±0.30(Predicted)
• CAS DataBase Reference: 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine(1010120-55-4)
• EPA Substance Registry System: 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine(1010120-55-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 1010120-55-4(Hazardous Substances Data)

Usage

General Description

5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine is a chemical compound with the molecular formula C6H5BrN5, and it belongs to the class of triazolopyridine derivatives. It is a heterocyclic compound that contains a bromo group and an amine group attached to the triazolopyridine ring. 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine has the potential to be used in pharmaceutical research and drug development due to its diverse range of biological activities, such as antiviral, anticancer, and antimicrobial properties. Its unique chemical structure makes it a promising candidate for further study and potential application in the field of medicinal chemistry and drug discovery.

Upstream product

• 19798-81-3 2-Amino-6-bromopyridine 
• 1010120-59-8 ethyl N-[(6-bromopyridin-2-yl)carbamothioyl]carbamate 

Downstream Products

• 1111106-76-3 5-(3-chlorophenyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine 
• 1142938-08-6 {4-[2-(cyclopropanecarbonylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl]phenyl}carbamic acid tert-butyl ester 
• 1142944-32-8 C₁₆H₁₅N₅O 
• 1142936-98-8 4-[2-(cyclopropanecarbonylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl]benzoic acid 
• 1206163-53-2 4-[2-(cyclopropanecarbonylamino)-[1,2,4]-triazolo[1,5-a]pyridin-5-yl]benzoyl chloride 
• 1142936-32-0 N-[5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]isobutyramide 
• 1142936-96-6 C₁₇H₁₇N₅O 
• 1142936-73-9 N-[5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]acetamide 
• 1142936-85-3 N-[5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzamide 
• 1142936-75-1 N-[5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]propionamide 
• 1010119-14-8 Cyclopropanecarboxylic acid (5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide 
• 1010119-18-2 Cyclopropanecarboxylic acid [5-(3-chloro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amide 
• 1142936-43-3 C₁₆H₁₃ClN₄O 
• 1010119-20-6 GLPG₀₆₃₄ 

Relevant articles and documents

Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors

Small molecule JAK inhibitors have been demonstrated efficacy in rheumatoid arthritis, inflammatory bowel disease, and psoriasis with the approval of several drugs. Aiming to develop potent JAK1/2 inhibitors, two series of triazolo [1,5-a] pyridine derivatives were designed and synthesized by various strategies. The pharmacological results identified the optimized compounds J-4 and J-6, which exerted high potency against JAK1/2, and selectivity over JAK3 in enzyme assays. Furthermore, J-4 and J-6 effectively suppressed proliferation of JAK1/2 high-expression BaF3 cells accompanied with acceptable metabolic stability in liver microsomes. Therefore, J-4 and J-6 might serve as promising JAK1/2 inhibitors for further investigation.

Triazolo pyridine compound and preparation method, medicinal composition and application thereof

The invention discloses a triazolo pyridine compound as well as a preparation method, a medicinal composition and application thereof. The compound is selected from a compound shown in a general formula I, or a tautomer, an enantiomer, a diastereoisomer,

JAK INHIBITORS

Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.